table ii.
Selected trials in platinum-sensitive relapse
| Reference (trial name) | Patients (n) | Arms | pfsa | p Value | osa | p Value |
|---|---|---|---|---|---|---|
| Parmar et al., 200323 (icon4/ago-ovar-2.2) | 802 | Conventional platinum-based | 10 months | 0.0004 | 24 months | 0.04 |
| Paclitaxel plus platinum | 13 months | 29 months | ||||
| Cantù et al., 200224 | 97 | Cyclophosphamide–doxorubicin–cisplatin | 15.7 months | 0.038 | 34.7 months | 0.043 |
| Single-agent paclitaxel | 9 months | 25.8 months | ||||
| Pfisterer et al., 200625 | 356 | Carboplatin | 5.8 months | 0.031 | 17.3 months | ns |
| Carboplatin plus gemcitabine | 8.6 months | 18.0 months | ||||
| Markman et al., 201026 | 61 | Carboplatin | 12 months | 0.02 | 31 months | 0.2 |
| Carboplatin–pegylated doxorubicin | 8 months | 18 months |
a
Median unless otherwise specified.
pfs = progression-free survival; os = overall survival; icon = International Collaborative Ovarian Neoplasm; ago = Arbeitsgemeinschaft Gynäkologische Onkologie; ns = nonsignificant.